Citizens Jmp Initiates Coverage on Sensei Biotherapeutics (NASDAQ:FTH)

Investment analysts at Citizens Jmp assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a note issued to investors on Monday, MarketBeat.com reports. The firm set an “outperform” rating and a $51.00 price target on the stock. Citizens Jmp’s price objective would indicate a potential upside of 79.77% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. Leerink Partners assumed coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price target on the stock. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target for the company. Finally, Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $54.00.

Sensei Biotherapeutics Trading Up 0.6%

NASDAQ:FTH opened at $28.37 on Monday. The company has a market capitalization of $38.02 million, a P/E ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics has a 12 month low of $6.32 and a 12 month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. As a group, sell-side analysts expect that Sensei Biotherapeutics will post -16.61 EPS for the current year.

Insider Activity

In other news, CEO Anand Kiran Parikh bought 2,806 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Brian C. Stephenson acquired 9,391 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was acquired at an average price of $26.13 per share, with a total value of $245,386.83. Following the acquisition, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This trade represents a 53.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 49,494 shares of company stock valued at $1,188,822. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the first quarter valued at approximately $22,758,000. Bank of America Corp DE raised its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP bought a new position in Sensei Biotherapeutics during the first quarter valued at approximately $4,188,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.